Survival
Analysis of Ki67 Protein Expression and Clinicopathological Features in Patients with Peritoneal Mesothelioma
Alternative Therapies in Health and Medicine 2023 December 8 [Link] Dujuan Yang, Yeping Zhou, Kongdan Lv Abstract Background: At present, there are many treatments for peritoneal mesothelioma, but the treatment of peritoneal mesothelioma is still facing great challenges. Distant metastasis is the main cause of poor prognosis and death of patients with peritoneal mesothelioma. Ki67…
Read MoreLAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
BMC Cancer 2023 December 7 [Link] Ken Arimura, Kenzo Hiroshima, Yoji Nagashima, Tadao Nakazawa, Akira Ogihara, Mami Orimo, Yasuto Sato, Hideki Katsura, Masato Kanzaki, Mitsuko Kondo, Etsuko Tagaya Abstract Background: Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor; novel LAG3 immune checkpoint inhibitors (ICIs) exhibit therapeutic activity in melanoma. The role of LAG3and ICIs…
Read MoreCombined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
Cancer Research Communications 2024 January 3 [Link] Jitendra Badhai, Nick Landman, Gaurav Kumar Pandey, Ji-Ying Song, Danielle Hulsman, Oscar Krijgsman, Gayathri Chandrasekaran, Anton Berns, Maarten van Lohuizen Abstract Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using…
Read MorePhase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
JTO Clinical and Research Reports 2023 October 12 [Link] Arkadiusz Z Dudek 1 2, Min X Xi 1, Katherine A Scilla 3, Hirva Mamdani 4, Benjamin C Creelan 5, Andreas Saltos 5, Tawee Tanvetyanon 5, Alberto Chiappori Abstract Introduction: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent…
Read MoreBrief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma – RIOMeso
Journal of Thoracic Oncology 2023 November 15 [Link] N McNamee, C Harvey, L Gray, T Khoo, L Lingam, B Zhang, U Nindra, P Y Yip, A Pal, T Clay, S Arulananda, M Itchins, N Pavlakis, S Kao, S Bowyer, V Chin, L Warburton, I Pires da Silva, T John, B Solomon, M Alexander, A Nagrial…
Read MoreGenomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma
European Journal of Cancer 2024 January [Link] Diego de Miguel-Perez, Edward M Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J Culligan, Katherine A Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R Hirsch, Andrea Wolf,…
Read MoreLong-Term Survival Analysis of Pleural Mesothelioma Patients Undergoing Surgery: Brief Report From a Tertiary Referral Centre
Clinical Lung Cancer 2023 October 24 [Link] Riccardo Orlandi, Giovanni Leuzzi, Luigi Rolli, Michele Ferrari, Alessia Stanzi, Camilla Valsecchi, Ugo Pastorino Abstract Objectives: to date, no consensus has been reached on the surgical gold-standard in pleural mesothelioma (PM). We retrospectively reviewed our experience as a tertiary referral centre, to compare short- and long-term survival of…
Read MoreA deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
Translational Cancer Research 2023 October 31 [Link] Wei Li, Minghang Zhang, Siyu Cai, Siqi Li, Biao Yang, Shijie Zhou, Yuanming Pan, Shaofa Xu Abstract Background: Malignant pleural mesothelioma (MPM) is a rare disease with limited treatment and poor prognosis, and a precise and reliable means to predicting MPM remains lacking for clinical use. Methods: In…
Read MoreTreatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma
eLife 2023 November 13 [Link] Akshat Sarkari, Sophie Korenfeld, Karina Deniz, Katherine Ladner, Phillip Wong, Sanyukta Padmanabhan, Rachel I Vogel, Laura A Sherer, Naomi Courtemanche, Clifford Steer, Kerem Wainer-Katsir, Emil Lou Abstract Disruption of intercellular communication within tumors is emerging as a novel potential strategy for cancer-directed therapy. Tumor-Treating Fields (TTFields) therapy is a treatment…
Read MoreThe Immunological Landscape of M1 and M2 Macrophages and Their Spatial Distribution in Patients with Malignant Pleural Mesothelioma
Cancers 2023 October 24 [Link] Caddie Laberiano-Fernandez, Camila Machado Baldavira, Juliana Machado-Rugolo, Auriole Tamegnon, Renganayaki Krishna Pandurengan, Alexandre Muxfeldt Ab’Saber, Marcelo Luiz Balancin, Teresa Yae Takagaki, Maria Aparecida Nagai, Vera Luiza Capelozzi, Edwin Roger Parra Abstract Background: Several tumor-associated macrophages (TAMs) have shown promise as prognosticators in cancer. Our aim was to validate the importance…
Read More